Effects of MNNG on Mitozolomide and DNA Crosslinking
Author Information
Author(s): N.W. Gibson, L.C. Erickson
Primary Institution: National Cancer Institute, Bethesda, Maryland and Loyola University, Stritch School of Medicine, Illinois
Hypothesis
MNNG pretreatment enhances the cytotoxic effects of mitozolomide by inducing DNA interstrand crosslinks in colon carcinoma cells.
Conclusion
MNNG pretreatment significantly increases the cytotoxicity of mitozolomide in HT-29 cells but has little effect on BE cells.
Supporting Evidence
- Mitozolomide and MCTIC were found to be more cytotoxic to BE colon carcinoma cells than to HT-29 cells.
- BE cells are deficient in the repair of 06-methylguanine lesions, while HT-29 cells are proficient.
- HT-29 cells become more sensitive to mitozolomide and MCTIC after MNNG pretreatment.
Takeaway
When certain cancer cells are treated with a chemical called MNNG before another drug, they become more sensitive to that drug's effects.
Methodology
The study involved treating two human colon carcinoma cell lines (HT-29 and BE) with mitozolomide and MCTIC, with and without MNNG pretreatment, and measuring DNA interstrand crosslinking and cytotoxicity.
Limitations
The applicability of MNNG pretreatment in vivo is limited due to its high carcinogenic potential.
Participant Demographics
The study focused on two human colon carcinoma cell lines: HT-29 (Mer+) and BE (Mer-).
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website